Loading...
The FDA and RU-486: Lowering the Standard for Women's Health
Citations
Altmetric:
Abstract
The Subcommittee on Criminal Justice, Drug Policy and Human Resources of the House Committee on Government Reform investigated the FDA's handling of RU486, focusing on its approval process, failures in ensuring proper dispensation, associated health issues, and evidence linking the drug to fatal infections. The report provides background on RU486, discusses FDA's alleged disregard for regulations during approval, and examines safety data gathered post-approval. It ultimately considers options for withdrawing the drug from the market due to significant risks to women's health.
Description
Date
2006-10-01
Journal Title
Journal ISSN
Volume Title
Publisher
Collections
Research Projects
Organizational Units
Journal Issue
Keywords
Staff Reports